Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

ABBVIE INC. (ABBV)

Pharmaceutical Preparations

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

1 NORTH WAUKEGAN ROAD
NORTH CHICAGO, IL

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/10/2012

Market Cap

341,578,008,612

Shares Outstanding

1,765,540,000

Weighted SO

1,765,537,421

Total Employees

N/A

Upcoming Earnings

07/25/2024

Similar Tickers

MRK --.--%

PFE --.--%

LLY --.--%

BMY --.--%

JNJ --.--%

AMGN --.--%

GILD --.--%

Beta

0.6230

Last Div

6.2000

Range

135.85-194.99

Chg

-0.0182

Avg Vol

5523501

Mkt Cap

341578008612

Exch

NYSE

Country

US

Phone

847 932 7900

DCF Diff

-901.2821

DCF

1063.3721

Div Yield

0.0317

P/S

6.2105

EV Multiple

23.7960

P/FV

50.4710

Div Yield %

3.1699

P/E

64.0023

PEG

4.4718

Payout

2.0159

Current Ratio

0.8068

Quick Ratio

0.7061

Cash Ratio

0.3133

DSO

77.8047

DIO

101.7628

Op Cycle

179.5676

DPO

706.7909

CCC

-527.2234

Gross Margin

0.7249

Op Margin

0.2700

Pretax Margin

0.1285

Net Margin

0.0972

Eff Tax Rate

0.2429

ROA

0.0377

ROE

0.5741

ROCE

0.1485

NI/EBT

0.7564

EBT/EBIT

0.4759

EBIT/Rev

0.2700

Debt Ratio

0.4976

D/E

10.4211

LT Debt/Cap

0.8954

Total Debt/Cap

0.9124

Int Coverage

7.7058

CF/Debt

0.2639

Equity Multi

20.9408

Rec Turnover

4.6912

Pay Turnover

0.5164

Inv Turnover

3.5868

FA Turnover

10.9496

Asset Turnover

0.3875

OCF/Share

10.5359

FCF/Share

10.0509

Cash/Share

7.4375

OCF/Sales

0.3389

FCF/OCF

0.9540

CF Coverage

0.2639

ST Coverage

1.4809

CapEx Coverage

21.7226

Div&CapEx Cov

1.6022

P/BV

50.4710

P/B

50.4710

P/S

6.2105

P/E

64.0023

P/FCF

19.2114

P/OCF

18.3546

P/CF

18.3546

PEG

4.4718

P/S

6.2105

EV Multiple

23.7960

P/FV

50.4710

DPS

6.1300

Latest Headlines (EST)

Benzinga Jun 20, 19:39 Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere GlobeNewswire Inc. Jun 05, 01:00 CEREVEL ALERT: Bragar Eagel & Squire, P.C. is Investigating Cerevel Therapeutics Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm GlobeNewswire Inc. May 25, 22:32 CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE The Motley Fool Apr 26, 22:05 4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off The Motley Fool Apr 25, 21:17 Why AbbVie Stock Topped the Market Today GlobeNewswire Inc. Apr 18, 21:12 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE GlobeNewswire Inc. Apr 14, 21:33 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE GlobeNewswire Inc. Apr 08, 04:50 Global Cosmeceuticals Market Size to Reach USD 182.17 Bn by 2032, at a CAGR of 9.6%, says Coherent Market Insights GlobeNewswire Inc. Mar 24, 00:30 Global Autoimmune Disease Therapeutics Market to reach USD 226,194.0 Million by 2035 Amid Rising Prevalence and Advancements in Biologic Therapies | Future Market Insights, Inc. GlobeNewswire Inc. Mar 22, 03:29 Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. The Motley Fool Mar 16, 22:19 1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction The Motley Fool Mar 09, 16:10 Is the SPDR S&P 500 ETF Trust the Smartest Investment You Can Make Today? The Motley Fool Feb 09, 19:30 3 Fabulous Dividend Stocks to Buy in February The Motley Fool Jan 27, 23:21 Why AbbVie Stock Popped While the Market Flopped on Monday GlobeNewswire Inc. Dec 08, 17:30 Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma GlobeNewswire Inc. Dec 08, 00:12 Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) The Motley Fool Nov 10, 14:30 3 Spectacular High-Yield Dividend Stocks to Buy in November The Motley Fool Sep 14, 13:15 Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More The Motley Fool Aug 25, 22:30 3 Unstoppable Dividend Stocks to Buy Right Now GlobeNewswire Inc. Aug 21, 22:30 Strategic Opportunities in Thin Film Drug Manufacturing Market to Expand to USD 16.5 Billion by 2034, Driving Industry Growth | Transparency Market Research Inc.

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
1.55 07/15/2024 06/20/2024 07/15/2024 08/15/2024
1.55 04/12/2024 02/15/2024 04/15/2024 05/15/2024
1.55 01/12/2024 10/27/2023 01/16/2024 02/15/2024
1.48 10/12/2023 09/08/2023 10/13/2023 11/15/2023
1.48 07/13/2023 06/22/2023 07/14/2023 08/15/2023
1.48 04/13/2023 02/16/2023 04/14/2023 05/15/2023
1.48 01/12/2023 10/28/2022 01/13/2023 02/15/2023
1.41 10/13/2022 09/09/2022 10/14/2022 11/15/2022
1.41 07/14/2022 06/23/2022 07/15/2022 08/15/2022
1.41 04/13/2022 02/17/2022 04/15/2022 05/16/2022
1.41 01/13/2022 10/29/2021 01/14/2022 02/15/2022
1.30 10/14/2021 09/10/2021 10/15/2021 11/15/2021
1.30 07/14/2021 06/17/2021 07/15/2021 08/16/2021
1.30 04/14/2021 02/18/2021 04/15/2021 05/14/2021
1.30 01/14/2021 10/30/2020 01/15/2021 02/16/2021
1.18 10/14/2020 09/11/2020 10/15/2020 11/16/2020
1.18 07/14/2020 06/17/2020 07/15/2020 08/14/2020
1.18 04/14/2020 02/20/2020 04/15/2020 05/15/2020
1.18 01/14/2020 11/01/2019 01/15/2020 02/14/2020
1.07 10/11/2019 09/06/2019 10/15/2019 11/15/2019
1.07 07/12/2019 06/20/2019 07/15/2019 08/15/2019
1.07 04/12/2019 02/21/2019 04/15/2019 05/15/2019
1.07 01/14/2019 11/02/2018 01/15/2019 02/15/2019
0.96 10/12/2018 09/07/2018 10/15/2018 11/15/2018
0.96 07/12/2018 06/14/2018 07/13/2018 08/15/2018
0.96 04/12/2018 02/15/2018 04/13/2018 05/15/2018
0.71 01/11/2018 10/26/2017 01/12/2018 02/15/2018
0.64 10/12/2017 09/08/2017 10/13/2017 11/15/2017
0.64 07/12/2017 06/23/2017 07/11/2017 08/15/2017
0.64 04/11/2017 02/17/2017 04/13/2017 05/15/2017
0.64 01/11/2017 10/31/2016 01/13/2017 02/15/2017
0.57 10/12/2016 09/09/2016 10/14/2016 11/15/2016
0.57 07/13/2016 06/16/2016 07/15/2016 08/15/2016
0.57 04/13/2016 02/18/2016 04/15/2016 05/16/2016
0.57 01/13/2016 10/30/2015 01/15/2016 02/16/2016
0.51 10/13/2015 09/11/2015 10/15/2015 11/16/2015
0.51 07/13/2015 06/19/2015 07/15/2015 08/14/2015
0.51 04/13/2015 02/19/2015 04/15/2015 05/15/2015
0.49 01/13/2015 10/21/2014 01/15/2015 02/13/2015
0.42 10/10/2014 09/19/2014 10/15/2014 11/17/2014
0.42 07/11/2014 06/19/2014 07/15/2014 08/15/2014
0.42 04/11/2014 02/20/2014 04/15/2014 05/15/2014
0.40 01/13/2014 12/12/2013 01/15/2014 02/14/2014
0.40 10/10/2013 09/19/2013 10/15/2013 11/15/2013
0.40 07/11/2013 06/20/2013 07/15/2013 08/15/2013
0.40 04/11/2013 02/15/2013 04/15/2013 05/15/2013
0.40 01/11/2013 01/07/2013 01/15/2013 02/15/2013